BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9570 related articles for article (PubMed ID: 19068464)

  • 1. [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
    Plótár V; Szentirmay Z; Orosz Z
    Magy Onkol; 2008 Dec; 52(4):363-73. PubMed ID: 19068464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical evaluation of necrotic malignant melanomas.
    Nonaka D; Laser J; Tucker R; Melamed J
    Am J Clin Pathol; 2007 May; 127(5):787-91. PubMed ID: 17439838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative distribution of S-100 protein and antigen HMB-45 in various types of melanomas and naevi.
    Mirecka J; Korabiowska M; Schauer A
    Pol J Pathol; 1995; 46(3):167-72. PubMed ID: 7496736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
    Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
    Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
    Steuhl KP; Rohrbach JM; Knorr M
    Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical characteristics of melanoma.
    Ohsie SJ; Sarantopoulos GP; Cochran AJ; Binder SW
    J Cutan Pathol; 2008 May; 35(5):433-44. PubMed ID: 18399807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
    Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
    Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
    Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
    Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compound melanocytic nevi with granular cell changes.
    El-Gamal HM; Robinson-Bostom L; Saddler KD; Pan T; Mihm MC
    J Am Acad Dermatol; 2004 May; 50(5):765-6. PubMed ID: 15097962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
    Gleason BC; Nascimento AF
    Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
    Lampert A; Thomine E; Lauret P; Hemet J
    Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas.
    Yu CH; Chen HH; Liu CM; Jeng YM; Wang JT; Wang YP; Liu BY; Sun A; Chiang CP
    J Oral Pathol Med; 2005 Oct; 34(9):540-5. PubMed ID: 16138892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.
    Sheffield MV; Yee H; Dorvault CC; Weilbaecher KN; Eltoum IA; Siegal GP; Fisher DE; Chhieng DC
    Am J Clin Pathol; 2002 Dec; 118(6):930-6. PubMed ID: 12472287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S100, HMB-45, and Melan-A negative primary melanoma.
    Shinohara MM; Deubner H; Argenyi ZB
    Dermatol Online J; 2009 Sep; 15(9):7. PubMed ID: 19930994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
    King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
    Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Malignant blue nevus].
    Rupec R; Eckert F; Ruzicka T
    Hautarzt; 1993 Mar; 44(3):164-6. PubMed ID: 8463099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mouse monoclonal antibody (FKH1) detecting human melanoma-associated antigens: production, partial characterization and immunohistochemical analysis].
    Fukaya T
    Hokkaido Igaku Zasshi; 1991 May; 66(3):300-10. PubMed ID: 1885156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
    Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
    Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal antibody HMB-45 in diagnosis of intra-ocular melanoma].
    Rohrbach JM; Steuhl KP; Thanos S
    Klin Monbl Augenheilkd; 1991 Oct; 199(4):274-7. PubMed ID: 1762354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 479.